ClinVar Miner

Submissions for variant NM_000251.3(MSH2):c.1276+1G>T

dbSNP: rs267607950
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000076088 SCV000107103 likely pathogenic Lynch syndrome 2019-06-21 reviewed by expert panel curation Interrupts canonical donor splice site
Ambry Genetics RCV000491760 SCV000580384 pathogenic Hereditary cancer-predisposing syndrome 2021-12-29 criteria provided, single submitter clinical testing The c.1276+1G>T intronic pathogenic mutation results from a G to T substitution one nucleotide after coding exon 7 of the MSH2 gene. This alteration has been observed in an individual whose colorectal tumor demonstrated high microsatellite instability and loss of MSH2/MSH6 expression on immunohistochemistry (IHC), and family history met Amsterdam criteria (Ambry internal data). This alteration has also been reported in two HNPCC families (Bisgaard ML et al. Hum Mutat, 2002 Jul;20:20-7; Nilbert M et al. Fam Cancer, 2009 Jun;8:75-83) and in an individual whose colorectal tumor demonstrated high microsatellite instability and loss of MSH2 expression on IHC (Mangold E et al. J Pathol, 2005 Dec;207:385-95). This alteration was detected in a Danish family with colorectal cancer and was found to segregate with disease within the family (Petersen SM et al. BMC Med Genet, 2013 Oct;14:103). This alteration has also been demonstrated to cause aberrant splicing that leads to an in-frame deletion of 16 amino acids in the MSH6/MSH3 interaction domain of the MSH2 protein (Betz B et al. J Cancer Res Clin Oncol, 2010 Jan;136:123-34; Petersen SM et al. BMC Med Genet, 2013 Oct;14:103). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Invitae RCV000707663 SCV000836768 pathogenic Hereditary nonpolyposis colorectal neoplasms 2023-08-18 criteria provided, single submitter clinical testing This variant disrupts the c.1276+1G nucleotide in the MSH2 gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 15849733, 19669161). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. This sequence change affects a donor splice site in intron 7 of the MSH2 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in the loss of 16 amino acid residue(s), but is expected to preserve the integrity of the reading-frame. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individuals with Lynch syndrome (PMID: 12112654, 16216036, 18566915, 24090359). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 90592). Studies have shown that disruption of this splice site results in the activation of a cryptic splice site in exon 7 (PMID: 24090359; Invitae). For these reasons, this variant has been classified as Pathogenic.
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV003237437 SCV002009347 pathogenic not provided 2021-11-03 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV002498365 SCV002812380 likely pathogenic Lynch syndrome 1; Muir-Torré syndrome; Mismatch repair cancer syndrome 2 2022-05-31 criteria provided, single submitter clinical testing
Myriad Genetics, Inc. RCV003452816 SCV004186726 likely pathogenic Lynch syndrome 1 2023-08-01 criteria provided, single submitter clinical testing This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.